AndhraNews.net
Home » Features » Health » Asthma

Asthma


About Asthma

In May 09, Researchers at the University of Pennsylvania have found that vitamin D may slow the progressive decline in asthmatics ability to breathe as a result of human airway smooth muscle (HASM) proliferation.

Second hand smoking

In issuing a groundbreaking report on secondhand smoke in June 2006, U.S. Surgeon General Richard Carmona stated, "The debate is over. The science is clear: Secondhand smoke is not a mere annoyance, but a serious health hazard that causes premature death and disease in children and nonsmoking adults." Secondhand smoke contains more than 4,000 chemicals, including at least 69 carcinogens. The Surgeon General found that secondhand smoke is a proven cause of lung cancer, heart disease, serious respiratory illnesses such as bronchitis and asthma, low birth weight and sudden infant death syndrome. The Surgeon General also found that secondhand smoke is responsible for tens of thousands of deaths in the United States each year, there is no safe level of exposure, and only smoke-free laws provide effective protection from secondhand smoke.

Smoke-free legislation

The Wisconsin Legislature has delivered a historic victory for health and the public's right to breathe clean air by passing legislation to make almost all workplaces, including all restaurants and bars, smoke-free. Gov. Jim Doyle has advocated for smoke-free legislation and is expected to sign the bill, which would make Wisconsin the 27th state to pass a strong smoke-free law that includes all restaurants and bars. Wisconsin joins 26 other states, Washington, D.C., and Puerto Rico in passing smoke-free legislation that covers restaurants and bars. The states are Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Iowa, Maine, Maryland, Massachusetts, Minnesota, Montana (extends to bars Oct. 1, 2009), Nebraska (June 1, 2009), New Hampshire, New Jersey, New Mexico, New York, North Carolina (Jan. 2, 2010), Ohio, Oregon, Rhode Island, South Dakota (July 1, 2009), Utah, Vermont and Washington. A growing number of countries have also passed nationwide smoke-free laws, including Bermuda, Bhutan, France, Iceland, Ireland, Italy, Lithuania, New Zealand, Norway, Panama, Sweden, Thailand, Turkey, the United Kingdom and Uruguay.

Recent research findings on Asthma

Asthma in News

The Trout Group to Host a "Trout Talk" Key Opinion Leader Meeting and Live Webcast on December 18 in New York City
NEW YORK, NY--(Marketwired - December 15, 2015) - The Trout Group, the leading global investor relations and strategic advisory firm servicing the life sciences industry, will host a KOL lunch and live webcast on December 18, at 12 pm ET series. A live webcast of the event will be available at trouttalk.troutgroup.com.

Avita Medical Sells Respiratory Business for $2.64m
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced that it has signed an agreement to sell its respiratory business to Medical Developments International (ASX: MVP) for $2.64m.

ABLYNX COMPLETES ENROLMENT OF THE FIRST-IN-INFANT PHASE I/IIa SAFETY STUDY WITH ITS ANTI-RSV NANOBODY AND EXTENDS THE TRIAL FOR YOUNGER INFANTS

Vision Source Announces Relationship With Central Ohio Primary Care
North America's largest, independent optometric alliance, Vision Source, announced today that it has entered into a relationship with Central Ohio Primary Care to provide eye health and vision services to their patient base. This collaboration will deliver improved outcomes for the patients of both organizations.

Proteostasis Therapeutics, Inc. Announces Management Changes to Strengthen Research and Development Organization
Proteostasis Therapeutics, Inc. (PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by defects in protein processing, announced today that Ben Munoz, Ph.D. has been promoted to Senior Vice President, Drug Discovery. PTI also announced the promotion of Po-Shun Lee, M.D. to Executive Vice President. Dr

Pieris Pharmaceuticals Announces First Cancer Immunotherapy Collaboration
BOSTON, MA--(Marketwired - December 08, 2015) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel bio therapeutics through its proprietary Anticalin® technology platform, today announced a research collaboration and license agreement with Roche in cancer immunotherapy (CIT)

Pieris Pharmaceuticals Presents Clinical Data for Its Hepcidin Antagonist Program, PRS-080, at the 2015 American Society of Hematology (Ash) Annual Meeting
BOSTON, MA--(Marketwired - December 07, 2015) - Pieris Pharmaceuticals, Inc

Pieris Pharmaceuticals to Present at the Oppenheimer 26th Annual Healthcare Conference on December 8th at 3:55 pm EST
BOSTON, MA--(Marketwired - December 01, 2015) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® bio therapeutic technologies, announced today that its President and CEO, Stephen Yoder, will present at the Oppenheimer 26th Annual Healthcare Conference

Silicon Valley's HBI Solutions Secures Series A Funding to Expand Real-Time Healthcare Analytics Services in the US and China
SAN FRANCISCO, CA--(Marketwired - December 01, 2015) - HBI Solutions, a Silicon Valley healthcare analytics company, will expand its business in US and global markets with $12.6 million in Series A funding led by Wonders Information Co. Ltd, based in Shanghai, China

Pieris Pharmaceuticals Achieves Payment Milestone in Sanofi Collaboration
BOSTON, MA--(Marketwired - November 30, 2015) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel bio therapeutics through its proprietary Anticalin® technology platform, announced today the achievement of the third payment-based milestone in its R&D collaboration with Sanofi, triggering a payment of an undisclosed amount to Pieris

Pieris Pharmaceuticals CEO to Present at the LD Micro Main Event on December 3rd
BOSTON, MA--(Marketwired - November 24, 2015) - Pieris Pharmaceuticals Inc. (NASDAQ: PIRS), a biotechnology company advancing novel bio therapeutics through its proprietary Anticalin® technology platform, announced today that its President and CEO, Stephen Yoder, will present at the LD Micro Main Event investor conference being held at the Luxe Sunset, Los Angeles, on December 1 - 3, 2015

Slim Trim 2000 Reviewed by Healthy Nutrition -- Pure Forskolin Formula Revealed
BAYSIDE, NY--(Marketwired - November 21, 2015) - With the discovery of an advanced formula for losing weight fast, trimming the tummy and attaining an in-shape body, Slim Trim 2000 has been introduced with a revolutionary ingredient "Forskolin," which was featured in a famous celebrity show as the finest source of breaking down body fat.

Obama Administration Drug Pricing Forum Should Address Urgently Needed Prescription Savings Realized Through Importation From Safe Canadian Pharmacies
As Americans continue to pay the highest prices in the world for basic health maintenance medications, the Campaign for Personal Prescription Importation (CPPI) is encouraged that U.S. Secretary of Health and Human Services, Sylvia Burwell, is conducting a drug pricing forum on November 20.

OxySure (OXYS) 3Q15 Results -- 14 Consecutive Growth Quarters -- Video News Alert on InvestmentPitch.com
VANCOUVER, BC--(Marketwired - November 20, 2015) - Medical device innovator, OxySure Systems (OTCQB: OXYS) announced results for the 3rd quarter 2015, reporting 14 consecutive quarters of growth.

Pieris Pharmaceuticals Collaborator Daiichi Sankyo Doses First Subject in a Phase 1 Clinical Study for Lead Partnered Anticalin Program
BOSTON, MA--(Marketwired - November 19, 2015) - Pieris Pharmaceuticals, Inc

ALCF Launches Billboard Campaign to #BeatLungCancer
SAN CARLOS, CA--(Marketwired - November 19, 2015) - The Bonnie J. Addario Lung Cancer Foundation (ALCF) launched a thought-provoking billboard campaign in Southern California this month to address the stigma surrounding lung cancer patients. The billboards feature 31-year-old Stage IV lung cancer survivor Emily Bennett Taylor and 32-year-old Stage IV lung cancer survivor Sandy Jauregui.

Eight Aurora Health Care Hospitals Earn Top Honors From The Joint Commission
MILWAUKEE, WI--(Marketwired - November 17, 2015) - Aurora Health Care today announced that eight of its hospitals have been recognized as 2014 Top Performers on Key Quality Measures® by The Joint Commission, the leading accreditor of health care organizations in the United States

OxySure (OXYS) Reports Third Quarter 2015 Financial Results With Annual Run Rate Approaching $5 Million
FRISCO, TX--(Marketwired - November 17, 2015) - OxySure Systems, Inc

NeoBiocon Partners with Novartis to Offer Vildagliptin for Diabetics in UAE
Business Wire IndiaNeoBiocon, a collaboration between Asia’s leading biopharmaceuticals company Biocon Ltd and Dr. B.R. Shetty, Chairman of the UAE-based Neopharma, announced today that it has partnered with Novartis Middle East FZE, to market Jalra (Vildagliptin) and Jalra-M (Vildagliptin + Metformin) in UAE

Purity Redefined by Livpure with Smart Air and Water Purifier
Business Wire IndiaLivpure, a leader & pioneer in touch based water purity, is now expanding its promise of delivering Purity – by extending its range from Water to Air, ensuring that you and your family enjoy a pure and healthy life

Cell MedX Corp. (CMXC), Announces the formation of an Advisory Board with John Sanderson MD as Chairman
Cell MedX Corp. (OTCBB: CMXC), (the "Company") announces the formation of an Advisory Board with Dr. John Sanderson MD as its Chairman. Dr. Sanderson will be organizing the development team and protocols necessary to advance the development of the Company's proposed technology, including the clinical trial phases and oversight of the results of those trials. Dr

ABLYNX OPENS RECRUITMENT FOR FIRST-IN-INFANT PHASE IIa STUDY WITH ITS ANTI-RSV NANOBODY, ALX-0171

One Woman's Story: Living and Helping Others With Inherited Lung Disorder
(Family Features) Wheezing, shortness of breath and chronic bronchitis are often associated with asthma or chronic obstructive pulmonary disease (COPD). However, they are also symptoms of a serious genetic form of emphysema called Alpha-1 Antitrypsin Deficiency, also known as Alpha-1.

MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting
MorphoSys AG /MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

New FDA Ruling Means More Medication Risk Information for Pregnant Women
BRENTWOOD, TN--(Marketwired - December 03, 2014) - In a move that was several decades in the making, the U.S. Food and Drug Administration (FDA) has published a final rule that requires prescription drugs and biological products include more detailed labeling about their risks during pregnancy and breastfeeding

Proteostasis Therapeutics Announces Appointment of Dr. Po-Shun Lee as Vice President of Clinical Development
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, today announced the appointment of Dr. Po-Shun Lee, MD, as Vice President of Clinical Development. Dr

Dr. Mariana Marcu, Top 3 Ways to Battle Allergies This Winter in NYC
Dr. Mariana Marcu addresses everyone's concerns this flu season, as she states, "Winter is the best time to treat your allergies!"

Horizon Pharma plc Announces Presentation of Data Showing Unmet Need in Rheumatoid Arthritis and the Positive Effect of RAYOS(R) (Prednisone) Delayed-Release Tablets in Reducing Joint Stiffness of RA Throughout the Day

Joint Commission Recognizes 1,224 Hospitals for Outstanding Performance on Key Quality Measures
Hospitals across the United States continue to improve their rates for complying with evidence-based care processes according to "America's Hospitals: Improving Quality and Safety: The Joint Commission's 2014 Annual Report." The results, released today, are based on data reported by more than 3,300 Joint Commission accredited hospitals in 2013

Horizon Pharma plc Announces Clinical Data on RAYOS(R) (Prednisone) Delayed-Release Tablets and VIMOVO(R) (Naproxen/Esomeprazole Magnesium) to Be Presented at the American College of Rheumatology Annual Meeting
Horizon Pharma plc (NASDAQ: HZNP) today announced that four abstracts related to RAYOS (prednisone) delayed-release tablets and one abstract on VIMOVO (naproxen/esomeprazole magnesium) will be presented during the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting taking place November 15 to 19, 2014 in Boston, MA.

Horizon Pharma plc Announces Favorable Markman Ruling in RAYOS(R) (prednisone) Delayed-Release Tablets Patent Infringement Litigation
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that a favorable Markman ruling has been issued by Judge Joseph E. Irenas of the United States District Court for the District of New Jersey in the patent infringement lawsuit filed by Horizon against Watson Laboratories, Inc

The Lung Association Launches Breathing as One to Unite Canadians in the Fight Against Lung Disease
TORONTO, ON--(Marketwired - November 03, 2014) - November is Lung Month, and The Lung Association is marking the event with the launch of Breathing as One, to bring patients, researchers and donors together to breathe new life into lung research.

Cellceutix's New Chief Operating Officer Dr. James Alexander Addresses Shareholders
Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antibiotic applications, is pleased to provide a strategic and operations update to shareholders from the Company's newly appointed Chief Operating Officer, Dr. James Alexander. Cellceutix disclosed in an 8-K filing with the U.S

Horizon Pharma plc Announces DUEXIS(R) Selected as Winner of Chicago Innovation Award
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that DUEXIS® (ibuprofen/famotidine) has been selected as one of the winners of the 13th annual Chicago Innovation Awards. Last night at Chicago's Harris Theater, Timothy P

Massachusetts League of Community Health Centers Launches AudioEye
AudioEye®, Inc. (OTCQB: AEYE) ("AudioEye") ("the Company"), creator of the Audio Internet® patented audio browsing and automated publishing technology platform, today announced that its technology has been launched at www.massleague.org, the official website of the Massachusetts League of Community Health Centers

Revalesio Names Bert van den Bergh President
Revalesio Corporation strengthened its executive leadership with the appointment of Bert van den Bergh as President. Mr. van den Bergh brings extensive industry experience to Revalesio as the company accelerates the development and commercialization of its therapeutic, RNS60

Orion Group Interim Report January-September 2014
ORION CORPORATION / INTERIM REPORT / JANUARY-SEPTEMBER 2014 / 21 October 2014 at 12:00 noon EEST

Horizon Pharma plc Announces Acquisition of U.S. Rights to PENNSAID(R) 2% From Nuvo Research Inc.
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today the acquisition of the U.S. rights to PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) from Nuvo Research Inc. (Nuvo) for a one-time payment of $45 million in cash. PENNSAID 2% is approved in the U.S

Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung Function Compared to Tiotropium
Theravance, Inc

Healthcare Experts Across India Come Together to Fight Pneumonia Amongst the Older Population of the Country
To commemorate World Pneumonia Day 2014, experts across renowned national institutes have initiated a campaign to spread maximum awareness about the symptoms and causes of Pneumonia among the elderly population in India. This campaign is an effort to protect adults aged 50 years and above from the deadly pneumococcal disease and thereby reduce the rate of death caused due to pneumonia

ANORO(TM) ELLIPTA(TM) Approved as First Once-Daily Dual Bronchodilator for the Treatment of COPD in the US
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc

Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share. The gross proceeds to Adamis from the offering are $22,134,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Adamis.

Sandoz receives first approval for AirFluSal® Forspiro®
Novartis International AG /Sandoz receives first approval for AirFluSal® Forspiro®. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Adamis Pharmaceuticals Announces Pricing of Public Offering of 3,720,000 Shares of Common Stock, Listing on NASDAQ, Reverse Stock Split
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the pricing of an underwritten public offering of 3,720,000 shares of common stock at an offering price of $5.95 per share. The gross proceeds to Adamis from this offering are expected to be approximately $22,134,000, before deducting underwriting discounts and commissions and other estimated offering expenses

National Association for Trusted Exchange on Fast Track to Facilitate Electronic Clinical Data Exchange Between Patients and Providers
Helping patients make their medical records more portable so they can coordinate their care online across multiple providers is the goal of an innovative pilot project currently involving three states, five health information organizations, and three personal health record (PHR) companies.

It's Not Too Late to Vaccinate -- Get Your Flu Vaccine Today
WASHINGTON, DC--(Marketwired - December 10, 2013) - "Flu season typically peaks in February and can last as late as May," says Dr. Anne Schuchat, Assistant Surgeon General of the U.S. Public Health Service and Director of CDC's National Center for Immunization and Respiratory Diseases. "We are encouraging people who have not yet been vaccinated this season to get vaccinated now."

LifeSci Advisors Initiates Coverage of Immune Pharmaceuticals
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP) (OTCQX: IMNP), a clinical stage biopharmaceutical company focused on developing antibody therapeutics for inflammatory diseases and cancer

Allerayde SAB Secures Grant from European Space Agency
Allerayde SAB, Inc. (OTCQB: ASAB) today announced that the company has secured a grant from the European Space Agency for costs associated with the patent process and creating a working prototype of a new integrated communicator device to be used in conjunction with AAA Pen®

GSK and Theravance Announce Positive Results From Pivotal Phase III Study for Fluticasone Furoate/Vilanterol in Asthma
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from a phase III efficacy and safety study of fluticasone furoate "FF"/vilanterol "VI" designed to support a potential filing for an asthma indication for adults in the US.

Allerayde SAB Takes Second Place in the Galileo Masters Competition, Earning Access to Key Research and Development Resources
Allerayde SAB, Inc. (OTCQB: ASAB) today announced that the company achieved second place in the prestigious Galileo Masters Competition organized by the European Space Agency.

Allerayde SAB Inc. Featured in Exclusive Interview on CEOinsiderTV.com
Allerayde SAB Inc. (OTCQB: ASAB) President and CEO, Michael Rhodes, shares his insight into effective emergency treatment of potentially life-threatening allergic reactions along with strategic directions for the upcoming year in an exclusive interview on CEOinsiderTV.com

Ingen's Patented Smart Nasal Cannula and Oxyview Increased Market Growth
Ingen Technologies Inc. (PINKSHEETS: IGNT), (http://ingen-tech

Adamis Pharmaceuticals Announces Proposed Public Offering
Adamis Pharmaceuticals Corporation (OTCQB: ADMP) today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of common stock and warrants. The filing covers up to $25 million in securities

AMA Adopts New Policies at Interim Meeting to Improve Health of Nation
WASHINGTON, DC--(Marketwired - November 19, 2013) - The American Medical Association (AMA), the premier national physician organization in the country, gathered physician and medical student leaders representing all aspects of medicine during its Interim Meeting and today voted to adopt new policies on emerging issues in public health and science to help improve the health of the nation.

RELVAR(R) ELLIPTA(R) Receives European Marketing Authorisation for the Treatment of Asthma and COPD
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced today that the European Commission has granted marketing authorisation for RELVAR® ELLIPTA®, which is now licensed across 31 European countries for the following uses:

Allerayde SAB to attend major Industry Event: CPhI Worldwide 2013
Allerayde SAB (OTCQB: ASAB) today announced that the company has participated in a leading Pharmaceutical Industry marketing and networking event, CPhI Worldwide 2013, with a goal of identifying potential new development and distribution partners.

International Stem Cell Corp. Featured in Exclusive QualityStocks Video Production
QualityStocks today announces the production of stimulating videos featuring International Stem Cell Corp. (OTCQB: ISCO), providing insight to the exciting capabilities of stem cell research and the company's revolutionary advances in the field of regenerative medicine.

LifeSci Advisors Initiates Coverage of NeoStem, Inc.
LifeSci Advisors, LLC

Iroko Pharmaceuticals Enters into Strategic Agreements to Expand Commercialization of ZORVOLEXTM (diclofenac) Outside the U.S.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that its affiliate, Iroko Pharmaceuticals Inc

Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat® to the treatment of asthma in adults aged 18 years and over
For Media outside the U.S., Canada and UK

PropThink: ViroPharma's Strengthening Financial Profile & Pipeline Indicate Long-Term Upside
Shares of ViroPharma (NASDAQ:VPHM) have been pressured in 2012 (falling over 17% as of December 26), as generic competition for one of its drugs has eaten into sales and profits. And while generic competition is never a welcome sign for pharmaceutical companies, ViroPharma is poised to overcome the issue, due to a strengthening balance sheet, and a promising pipeline

Horizon Pharma to Receive Approval of DUEXIS(R) From the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA), based on the favorable recommendation of their Commission on Human Medicines (CHM), will grant a Marketing Authorization (MA) for DUEXIS® (ibuprofen/famotidine), pending review of updated licensing documents which the Company has provided to the MHRA

Rigel Recovers On 2013 Hope For Its Rheumatoid Arthritis Drug
By Brian Wilson, Lead Contributor

Medecision Awarded Full NCQA Disease Management Systems Certification
Medecision, the leader in collaborative healthcare management technology, today announced that it has earned National Committee for Quality Assurance (NCQA) Disease Management Systems Certification for the full suite of Aerial™ solutions including Disease Management (DM) Clinical Programs.

Theravance Announces Initiation of Phase 2b Study With Its LAMA Candidate, TD-4208, for the Treatment of COPD
Theravance, Inc. (NASDAQ: THRX) announced the initiation of a dose ranging Phase 2b study with TD-4208 as a nebulized aqueous solution in patients with moderate to severe COPD. TD-4208 is an investigational inhaled long-acting muscarinic antagonist (LAMA), discovered using Theravance's multivalent approach to drug design

Consumer Fraud Center Urges Amazon to Halt Uninspected Shipments From China Into Its Warehouses Because of Threat of Carcinogens
Coming on the heels of a legal action launched by an environmental advocacy group against several major retailers concerning the presence of suspected carcinogens in baby products, the Consumer Fraud Center today joined in urging Amazon.com, Inc

Aptalis Pharma U.S., Inc. Announces U.S. Commercial Availability of ULTRESA(TM) (Pancrelipase) Delayed-Release Capsules
Aptalis Pharma U.S., Inc., a global specialty pharmaceutical company focused on gastrointestinal diseases and cystic fibrosis (CF), announced that ULTRESA™ (pancrelipase) delayed-release capsules are now commercially available in the U.S

Horizon Pharma Begins Initial Commercial Launch of RAYOS(R) (prednisone) Delayed-Release Tablets in the United States
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that RAYOS® (prednisone) delayed release tablets are now available to U.S. physicians to treat a broad range of diseases, including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD)

Orion is planning to apply for a marketing authorisation for combined budesonide-formoterol formulation of the Easyhaler® product family
ORION CORPORATION STOCK EXCHANGE RELEASE 30 NOVEMBER 2012 at 1:10  PM  EET

Trimedyne Announces the Development of New Breakthrough Laser Devices
TRIMEDYNE, INC. (OTCBB: TMED) today announced it has patented and filed patent applications covering several new laser devices ("Devices") designed to treat medical conditions that affect millions of people in the United States and many more millions of people throughout the world.

LA County Smokers Fall Below One Million for the First Time
In honor of the 37th Annual Great American Smokeout, the Los Angeles County Department of Public Health released a new report showing the number of adult smokers in LA County fell below one million for the first time since the Los Angeles County Health Survey was initiated in 1997

Veidekke ASA : Veidekke to build more flats at Ensjø in Oslo
 

Horizon Pharma Announces Third Quarter 2012 Financial Results and Provides Business Update
Horizon Pharma, Inc. (NASDAQ: HZNP) today provided an update on the Company's business and announced financial results for the third quarter and nine months ended September 30, 2012.

Horizon Pharma Presents Clinical Data Demonstrating RAYOS(R) (prednisone) Delayed-Release Tablets Reduce Morning Stiffness in Patients With Active Rheumatoid Arthritis
Horizon Pharma, Inc

Horizon Pharma Announces Clinical Data on RAYOS(R) (Prednisone) Delayed-Release Tablets to Be Presented at the American College of Rheumatology Annual Meeting
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that two studies on its recently approved treatment RAYOS® 5 mg (prednisone) delayed-release tablets will be presented during the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting, November 9-14 in Washington, D.C.

Novartis to start construction of new biotechnology facility in Singapore with an investment of over USD 500 million
Novartis International AG /Novartis to start construction of new biotechnology facility in Singapore with an investment of over USD 500 million . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Theravance Reports Third Quarter 2012 Financial Results
Theravance, Inc. (NASDAQ: THRX) reported today its financial results for the quarter ended September 30, 2012. Revenue for the third quarter of 2012 was $1.4 million. Net loss for the third quarter of 2012 was $34.7 million or $0.37 per share. Cash, cash equivalents, and marketable securities totaled $362.4 million as of September 30, 2012.

MegaFood Adds D3 and B Complex to Award-Winning Children's Multivitamins
If you are like most time-crunched parents the idea of fresh home-cooked meals are rarely a reality, which is why pediatricians recommend multivitamin supplementation for children who cannot get their vitamins through whole foods. But MegaFood relieves parents of the guilt by providing the only whole food supplements for children

Orion Group Interim Report January-September 2012
ORION CORPORATION / INTERIM REPORT / JANUARY-SEPTEMBER 2012 / 23 October 2012 at 12:00 noon EEST

2013 International CES to Feature Major Consumer Technology Trends and Inspiring Innovations
From wireless wallets to cloud-based services, app integration, digital health and fitness devices and beyond, the 2013 International CES® will feature an array of top consumer technology products and trends, including inspiring innovations across a range of hot products and categories

Now, e-cigarettes that mimic sensation of smoking sans lethal effects
Companies, including some of the biggest names in tobacco, are up to launching a generation of devices that deliver a hit of nicotine and mimic the experience of smoking without the lethal effects in a bid to eradicate harmful cigarettes.

Treatments for asthma, allergies and arthritis to become safer
A missing link between the body's biological clock and sugar metabolism system has been discovered, which may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.

Diesel exhaust and house dust worsen asthma
Scientists have found that diesel exhaust particulates (DEP) and house dust extract (HDE) causes pulmonary inflammation that aggravate asthma.

1 in 4 severe asthma attacks can be cured with proper medication
Adhering to medication as per prescription can prevent one-quarter of severe asthma attacks, a new study has suggested.

Gwyneth Paltrow offers cures for New Year hangover
Gwyneth Paltrow has offered up some best hangover cures in her blog to help revellers ring in the New Year without a headache.

Sugar free strawberries cultivated in Uttarakhand
Farmers in Ramnagar in Uttarakhand's Nainital District have taken up sugar free strawberry cultivation with an aim to ensure that the patients suffering from diabetes are able to consume it.

Rolling out their breathe in 'beedis'

Mirth Selected to Power Crescent City Beacon Community
Mirth Corporation, a global leader in commercial open source healthcare information technology, announced that the Crescent City Beacon Community (CBCC), one of 17 federally funded Beacon Communities nationwide, will utilize their full suite of interoperability and care management solutions to achieve its innovative vision for connected care across the greater New Orleans area.

Clermont, Florida Chiropractor Releases New Website to Educate Public About Chiropractic Care
Dr. Kurtis Michaux, a Clermont chiropractor, has just launched a new chiropractic website for his practice, Michaux Family Chiropractic, geared towards patients and the general public throughout the Florida communities of Clermont, Minneola, Davenport, Four Corners, Windemere, and Groveland

BioServe Expands Relationship With Fox Chase Cancer Center
BioServe today announced an expanded relationship with Fox Chase Cancer Center, a foundation member of the BioServe Network of leading sample biorepositories. In this expanded relationship, BioServe will be working with Fox Chase to provide clients with next generation sequencing capabilities

Comment on this story

Share